Newsletter
|
Hi, it’s Elizabeth here with this month’s Co-Founders’ Corner. Due to significant changes in policy and public opinion, access to psychedelic therapy is expanding, and general interest in the subject is hitting new highs.
While much attention is focused on clinical research outcomes and state licensure programs—such as the recent Natural Medicine Program in Colorado—the groundbreaking work done by the drug development industry often goes unnoticed. Still, it has been instrumental in driving awareness and adding legitimacy.
Fluence partners with a dozen leading drug developers and is actively involved in the latest advancements in a wide variety of psychedelic therapy treatments. These organizations are at the forefront of translating promising research into tangible treatments that could revolutionize mental health care.
As a co-founder of Fluence, I've observed the rapid evolution of breakthrough treatments for mental health disorders with a keen eye. Lately, I’ve seen growing interest from investors with the financial resources to advance clinical trials and bring these promising treatments to patients.
I am convinced that the approval and accessibility of these innovative treatments will increase over time, and I am excited to see an increase in new developments and promising clinical trial results, such as the work done by our partners at Tactogen.
Later this month, we will host a webinar featuring Matthew Baggott—Lead Research Scientist and CEO of Tactogen—exploring the latest advancements in MDMA and entactogen development and uncovering what the work of drug development organizations actually entails.
Entactogens offer unique experiences that can facilitate profound emotional processing and healing. With the right investment, careful research design, and proper therapist training, clinical trials for these compounds can progress with more rigour than ever before. This could help drive promising results and potentially lead to FDA approval and broader accessibility of these treatments in the coming years.
Progress wouldn’t be possible without the tireless work of the many passionate and diligent people working at drug development companies and clinical research sites worldwide.
Their efforts, combined with organizations like Fluence, prepare mental health professionals, paving the way for this paradigm shift in mental health treatment.
I’m proud to be part of this movement and of our continuing work preparing the next generation of psychedelic therapists.
Thanks,
Elizabeth Nielson, Fluence Co-Founder
This month, we're excited to shine the spotlight on Dr. Brian Pilecki, a clinical psychologist who is making waves in the field of psychedelic therapy. With a specialization in anxiety disorders, trauma, and PTSD, Dr. Pilecki brings a unique blend of expertise to his practice.
Brian is passionate about disseminating knowledge in the field. He has delivered numerous workshops on psychedelic-related topics and co-hosts the podcast "Altered States of Context," which explores the fascinating intersection of psychedelics and psychotherapy.
His work represents the cutting edge of psychedelic therapy, bridging traditional psychological approaches with emerging treatments to revolutionize mental health care.
Brian is one of the expert Fluence trainers on our Psilocybin Facilitation Professional Certificate and is leveraging his knowledge and training to help the next generation of psychedelic therapists become certified Psilocybin Facilitators.
Learn more about Brian’s upcoming course.
In our upcoming webinar, Matthew Baggott, Lead Research Scientist and CEO of Tactogen, will discuss the latest advancements in the development of MDMA and other entactogens.
Discover how groundbreaking research is transforming the field of psychedelics and redefining possibilities in medicine and learn about:
Their therapeutic potential
Challenges in clinical trials
Future applications in mental health treatment
Join this unique opportunity to hear from a leading expert and gain valuable insights into the rapidly evolving world of psychedelic science.
Date: Feb 27, 2025
Time: 2 PM - 3 PM ET
Join our upcoming Open House event, where Admissions Director Dr. Alex Camargo will explore our Essentials of Psychotherapy course.
Learn what the entry course offers practitioners and how it can lead to professional certificates in Psilocybin Facilitation, Ketamine-assisted Psychotherapy and Psychedelic Harm Reduction and Integration.
Date: Feb 18, 2025
Time: 3 PM - 4PM ET
Psilocybin Facilitation
March 11 - August 9, 2025
Ketamine-Assisted Psychotherapy
March 11 - July 29, 2025
Psychedelic Harm Reduction and Integration Therapy
March 11 - December 8, 2025
Beyond Words: Unlocking the Language and Meaning of Psychedelic Experience
This 8-week course helps psychedelic therapists guide their clients in articulating and exploring profound but often ineffable psychedelic experiences.
March 26 - May 14, 2025
Trainer: Jeffrey Guss, MD
How an Activist Group Helped Torpedo MDMA Therapy
The fallout from the F.D.A.’s rejection of a new treatment for PTSD worries researchers and experts who fear other psychedelic drugs in the pipeline could be jeopardized.
5 Therapy Trends to Watch in 2025
The inside scoop on the hot clinical developments you won’t want to miss in the coming year.
Relationality and Ethics in MDMA-Assisted Therapy
A response to the special issue of the American Journal of Bioethics highlighting the importance of grounding psychedelic-assisted therapy (PAT) in a relational ethical framework.
